Chugai OTC Stock Performance

CHGCF -  USA Stock  

USD 32.52  3.72  10.26%

The firm shows a Beta (market volatility) of 0.8313, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Chugai's beta means in this case. As returns on the market increase, Chugai Pharmaceutical returns are expected to increase less than the market. However, during the bear market, the loss on holding Chugai Pharmaceutical will be expected to be smaller as well. Even though it is essential to pay attention to Chugai Pharmaceutical historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Chugai Pharmaceutical exposes twenty-one different technical indicators, which can help you to evaluate its performance. Chugai Pharmaceutical has an expected return of -0.26%. Please be advised to confirm Chugai Pharmaceutical treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Chugai Pharmaceutical performance from the past will be repeated at some point in the near future.

Chugai O TC Stock Performance 

 
Refresh
Chugai Performance
0 of 100
Over the last 90 days Chugai Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in January 2022. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more

Chugai Price Channel

Quick Ratio3.08
Fifty Two Week Low34.49
Payout Ratio39.24%
Fifty Two Week High46.25
Trailing Annual Dividend Yield143.98%

Chugai Pharmaceutical Relative Risk vs. Return Landscape

If you would invest  3,910  in Chugai Pharmaceutical on September 5, 2021 and sell it today you would lose (658.00)  from holding Chugai Pharmaceutical or give up 16.83% of portfolio value over 90 days. Chugai Pharmaceutical is currently producing negative expected returns and takes up 2.3538% volatility of returns over 90 trading days. Put another way, 20% of traded otc stocks are less volatile than Chugai, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming the 90 days horizon Chugai Pharmaceutical is expected to under-perform the market. In addition to that, the company is 2.81 times more volatile than its market benchmark. It trades about -0.11 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.02 per unit of volatility.

Chugai Pharmaceutical Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Chugai Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Chugai Pharmaceutical, and traders can use it to determine the average amount a Chugai Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1121

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsCHGCF
Estimated Market Risk
 2.35
  actual daily
 
 20 %
of total potential
 
2020
Expected Return
 -0.26
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.11
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Chugai Pharmaceutical is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chugai Pharmaceutical by adding it to a well-diversified portfolio.

About Chugai Pharmaceutical Performance

To evaluate Chugai Pharmaceutical OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Chugai Pharmaceutical generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Chugai OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Chugai Pharmaceutical stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Chugai's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. Chugai Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 7555 people.

Things to note about Chugai Pharmaceutical

Checking the ongoing alerts about Chugai Pharmaceutical for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Chugai Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Chugai Pharmaceutical Alerts

Equity Alerts and Improvement Suggestions

Chugai Pharmaceutical generated a negative expected return over the last 90 days
About 60.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases - Yahoo Finance
Continue to Trending Equities. Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Chugai OTC Stock analysis

When running Chugai Pharmaceutical price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Chugai Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chugai Pharmaceutical. If investors know Chugai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chugai Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chugai Pharmaceutical is measured differently than its book value, which is the value of Chugai that is recorded on the company's balance sheet. Investors also form their own opinion of Chugai Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Chugai Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chugai Pharmaceutical's market value can be influenced by many factors that don't directly affect Chugai Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chugai Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine Chugai Pharmaceutical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chugai Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.